Advanced Malignancies
Conditions
Brief summary
IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.
Detailed description
Hsp90 controls the proper folding, function, and stability of various client proteins within cells. Many of the clients of Hsp90 (such as Akt, Bcr-Abl, EGFR, Flt-3, c-Kit and PDGFR α) are oncoproteins or important cell-signaling proteins, and therefore are critical for tumor cell growth and survival. Inhibition of Hsp90 results in degradation of these proteins, which abrogates growth and survival signaling and leads to tumor cell death.
Interventions
DRUGIPI-493
Capsules, Multiple Schedules
Sponsors
Infinity Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must have pathologically confirmed advanced solid tumors 2. Progressive disease for their advanced solid tumor 3. Patients must be ≥18 years of age 4. Performance status of 0 or 1. 5. Not Pregnant by blood or urine test, and be willing to use adequate methods of birth control
Exclusion criteria
1. Treatment with the following therapies within the specified time period: * Any chemotherapy (other than nitrosoureas or mitomycin C), radiation therapy (other than whole brain irradiation \[WBI\]), surgery, hormonal therapy, or investigational therapy within 4 weeks of the start of IPI 493 administration * Any tyrosine kinase inhibitor (e.g., erlotinib, imatinib) within 2 weeks * Whole brain irradiation therapy within 3 months * Stereotactic cranial radiosurgery (SRS) within 4 weeks * Nitrosoureas or mitomycin C within 6 weeks * Any known Hsp90 inhibitor 2. Toxicities from prior therapies must have resolved to ≤ Grade 1 or baseline 3. Concurrent administration of the medications or foods , which are known to inhibit or induce CYP3A activity to a clinically relevant degree, is not allowed. 4. Concurrent treatment with any agent known to prolong the QTc interval 5. Known human immunodeficiency virus (HIV) positivity. 6. Inadequate hematologic function defined by absolute neutrophil count (ANC) \< 1,500 cells/mm3, a platelet count \< 100,000/mm3, and a hemoglobin \< 9.0 g/dL 7. Inadequate hepatic function 8. Inadequate renal function 9. Sinus bradycardia 10. Baseline QTcF \> 450 msec in males; QTcF \> 470 msec in females. 11. Presence of left bundle branch block (LBBB), right bundle branch block (RBBB) if accompanied by left anterior hemiblock, bifascicular block or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker. 12. Patients who have received \> 450 mg/m2 of any anthracycline during prior chemotherapy must have a baseline left ventricular ejection fraction (LVEF) \> 40%. 13. Active keratitis or keratoconjunctivitis. 14. Presence of active infection or systemic use of antibiotics within 72 hours of treatment. 15. Patients with a clinically active brain metastasis 16. Patients with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months. 17. Significant co-morbid condition or disease which in the judgment of the Investigator would place the patient at undue risk or interfere with the study. Examples include, but are not limited to cirrhotic liver disease, sepsis, and other conditions. 18. Women who are pregnant or lactating. 19. Patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation and meet any of the following criteria are excluded: * Have been on a stable dose of anticoagulation for \<1 month * Have had a Grade 2, 3 or 4 hemorrhage in the past month * Are experiencing continued symptoms from their venous thromboembolic event * Patients who have had a venous thromboembolic event but do not meet any of the above three criteria are eligible for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the safety and maximum tolerated dose (MTD) of IPI 493 | ongoing |
| To recommend a dosing regimen (dose and schedule) for subsequent studies of IPI 493 | ongoing |
Countries
United States
Outcome results
None listed